Sitagliptin
- 1 February 2007
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 6 (2) , 109-110
- https://doi.org/10.1038/nrd2245
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin AloneDiabetes Care, 2006
- Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClinical Therapeutics, 2006
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006
- The biology of incretin hormonesCell Metabolism, 2006
- Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 DiabetesAnnals of Internal Medicine, 2005
- (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 DiabetesJournal of Medicinal Chemistry, 2004
- Therapeutic Strategies Based on Glucagon-Like Peptide 1Diabetes, 2004
- Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 DiabetesDiabetes Care, 2002
- Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26Proceedings of the National Academy of Sciences, 2000